MZR01 : Mizoribine

CAS Name: 5-Hydroxy-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide

CAS Number: 50924-49-7

Mizoribine is a nucleoside produced by fermentation (Eupenicillium brefedianum) or by synthesis from acadesine, it shows antibiotic, cytotoxic and immunosuppressive activity.

Physico-Chemical Properties:

White or off white crystalline powder; mp > 200 DC (dec); [a]D27 -35 (c = 0.8 in water); pKa 6.75; uv max (water): 245, 279 nm (E 250, 580); Soluble in water; Slightly soluble in methanol, ethanol. Insoluble in most organic solvents.

References:

Isolation, Purification and Structure Determination:

K. Mizuno et al., US 3888843 (1975 to Toyo Jozo);
K. Mizuno et al., J. Antibiot. 27, 775 (1974).

Synthesis:

M. Hayashi et al., Chem. Pharm. Bull. 23, 245 (1975);
K. Fukukuwa et al., Chem. Pharm. Bull. 32, 1644 (1984).

HPLC analysis:

K. Takada et al., J. Chromatog. 222, 156 (1981).

   

ACD01 : Acadesine

CAS Name: 5-Amino-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide

CAS Number: 2627-69-2

Acadesine, also known as 5-Amino-Imidazole-4-CarboxAmide-1-beta-4-ribofuranoside ("AICA"-riboside), is an AMP-activated protein kinase activator which is used for the treatment of acute lymphoblastic leukemia and may have applications in treating other disorders such as diabetes. Acadesine is an adenosine regulating agent developed by PeriCor Therapeutics and licensed to Schering-Plough in 2007 for phase III studies. The drug is a potential first-in-class agent for prevention of reperfusion injury in CABG surgery. Schering began patient enrollment in phase III studies in May, 2009.